Trial Profile
A Phase 2b, Multicenter, Double-masked, Randomized Study Evaluating the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy Secondary to Age Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2020
Price :
$35
*
At a glance
- Drugs Palucorcel (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRELUDE
- Sponsors Janssen Research & Development
- 02 Jul 2019 Status changed from active, no longer recruiting to completed.
- 08 Feb 2019 Planned End Date changed from 31 May 2019 to 20 Jun 2019.
- 24 Aug 2018 Planned primary completion date changed from 29 Dec 2018 to 31 May 2019.